Ma et al. (2017) reported that the combination of the CDK4/6 inhibitor palbociclib and anastrozole can inhibit the proliferation of tumor cells and reduce drug resistance in patients with ER+/HER2- breast cancers (Ma et al., 2017). The gene discussed is ERBB2; the disease is breast cancer.